pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,808 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1782Endpoints1389Fierce Biotech708BioSpace698BioPharma Dive524raps234onclive165fda recalls113fda medwatch
therapy area
allOncology12325Rare Disease3219Immunology2863Cardiology2745Hematology2177Pulmonology2143Vaccines
  • FDA reports most U.S. infant formulas contain only trace or undetectable levels of heavy metals and other contaminants
    The Food and Drug Administration examined 312 samples drawn from 16 major infant‑formula brands, looking for residues of heavy metals, pesticides, PFAS and phthalates. Across the board the agency…
    STAT · 6mo agoRegulatoryPositive↗ source
  • AI researcher Kyunghyun Cho leaves Genentech to explore pharma applications at Endpoints AI Day
    Kyunghyun Cho, a noted AI researcher, announced that he has left Genentech to pursue independent work in pharmaceutical applications of machine learning. He will discuss his new focus at Endpoints…
    Endpoints · 6mo agoPositive↗ source
← prev
page 148 of 153
next →
111
globenewswire health73
fda press59
1796
Psychiatry & CNS1204
Ophthalmology1060
Pain777
Endocrinology & Metabolism776
Nephrology760
  • MPM BioImpact adds three China-origin drug programs to K2 Therapeutics portfolio
    MPM BioImpact, a biotech investment firm, is intensifying its "best of both worlds" approach by bringing drug candidates that originated in China to a broader market. Over the past year its portfo…
    Endpoints · 6mo agoDealPositive↗ source
  • Medical students debate how to improve nutrition and preventive health training in med schools
    The article is an opinion piece that examines medical students' views on Health Secretary Robert F. Kennedy's call for stronger nutrition and preventive medicine education in medical school. It fe…
    STAT · 6mo agoNeutral↗ source
  • Report shows modest health equity gains but experts warn they may not last
    A new Commonwealth Fund report covering 2022 to 2024 highlights several state-level actions that narrowed health disparities. Two states broadened Medicaid eligibility, many expanded postpartum cov…
    STAT · 6mo agoNegative↗ source
  • Federal autism advisory committee meets for first time in 19 months, targets support for profound autism
    The Interagency Autism Coordinating Committee held its first session in 19 months, convening after Health Secretary Robert F. Kennedy Jr. removed most of the panel’s scientific experts and appointe…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Food safety experts warn of talent loss at USDA amid broader health policy updates
    Food safety experts cautioned that the USDA is experiencing a significant loss of scientific talent, which could affect its ability to oversee food safety programs. The autism advisory committee,…
    STAT · 6mo agoNeutral↗ source
  • Alternative medicine often feels more personal than conventional care, says physician
    Dr. Hannah Kerman, a New York physician, writes that many patients turn to acupuncturists or massage therapists because they feel more attended to than during typical medical visits. She describes…
    STAT · 6mo agoNeutral↗ source
  • Pfizer settles with generics to extend tafamidis patent until 2031, protecting revenue
    Pfizer announced settlements with three generic manufacturers-Dexcel Pharma, Hikma Pharmaceuticals and Cipla-to delay the launch of generic versions of tafamidis, the active ingredient in its rare‑…
    BioPharma Dive · 6mo agoDealPositive↗ source
  • Boehringer’s dual-acting obesity shot survodutide meets primary goal in Phase 3, showing strong weight loss and muscle-preserving effect
    Boehringer Ingelheim announced that its dual-acting injectable obesity therapy, survodutide, achieved its primary endpoint in a Phase 3 study. Participants receiving the drug lost significantly mo…
    BioPharma Dive · 6mo agoPositive readoutPositive↗ source
  • FDA urges Amgen to withdraw Tavneos after alleging data manipulation by former developer
    The FDA has sent a formal letter to Amgen recommending that the company pull its drug Tavneos from the market. The agency says new information shows the original approval filings from ChemoCentryx…
    BioPharma Dive · 6mo agoRegulatoryNegative↗ source
  • FDA says trial manipulation undermines approval of ChemoCentryx's Tavneos, now owned by Amgen
    The U.S. Food and Drug Administration has announced that it believes the pivotal trial supporting the approval of Tavneos was manipulated. The agency says ChemoCentryx, which was acquired by Amgen…
    Endpoints · 6mo agoRegulatoryNegative↗ source
  • Eli Lilly partners with AI startup Profluent to develop next-generation gene editors
    Eli Lilly announced a collaboration with AI-focused biotech Profluent to create advanced gene-editing tools that could insert whole genes into patients. The partnership is intended to move beyond…
    STAT · 6mo agoDealPositive↗ source
  • Incyte reports positive Phase 3 results for povorcitinib in nonsegmental vitiligo, plans FDA filing
    Incyte announced that its oral JAK1 inhibitor povorcitinib achieved positive outcomes in two Phase 3 trials targeting nonsegmental vitiligo. The studies met their primary endpoints, demonstrating…
    Endpoints · 6mo agoPositive readoutPositive↗ source
  • AbbVie eyes pan-RAS market with up to $1.45 B option to acquire Kestrel
    AbbVie announced it has signed an agreement that gives it the right to acquire Kestrel Therapeutics for up to $1.45 billion. The deal would give AbbVie access to Kestrel’s pipeline focused on pan-…
    Endpoints · 6mo agoDealPositive↗ source
  • Novartis CEO says Trump’s drug pricing plan creates a very difficult situation for makers and patients
    Novartis chief executive Vas Narasimhan warned that the United States drug‑pricing policy under President Trump presents a "very difficult situation" for both drugmakers and patients. He said the…
    STAT · 6mo agoRegulatoryNegative↗ source
  • BridgeBio's heart drug Attruby exceeds sales expectations, shifting investor outlook
    BridgeBio prepared to sell its heart drug Attruby on its own, prompting skepticism from investors and analysts who doubted the company could compete with larger rivals. The drug far outperformed f…
    BioPharma Dive · 6mo agoPositive↗ source
  • Novartis CEO warns of impact from Germany's €60 billion healthcare spending cuts
    Novartis chief executive Vas Narasimhan said the company is very disappointed by Germany's proposal to reduce healthcare spending by more than €60 billion. He expressed concern that the cuts could…
    Endpoints · 6mo agoRegulatoryNegative↗ source
  • AIDS advocacy group sues Trump administration over hidden Gilead HIV-prevention settlement
    The AIDS advocacy group PrEP4All filed a lawsuit against the Trump administration, alleging it failed to disclose a research and development agreement with Gilead Sciences. The agreement was part…
    STAT · 6mo agoRegulatoryNegative↗ source
  • FDA launches AI-driven pilot to review trial data in real time, aiming to speed clinical studies
    Washington officials said the Food and Drug Administration is starting a new program to speed clinical trials by reviewing data as it is generated. The first pilots will use real-time data from tr…
    STAT · 6mo agoRegulatoryPositive↗ source
  • FDA launches pilot to collect real-time clinical trial data
    The FDA announced a new pilot program that will gather clinical trial information as it is generated, allowing reviewers to see data in real time. The agency says this approach could speed up eval…
    Endpoints · 6mo agoRegulatoryNeutral↗ source
  • Pfizer secures two-year extension on Vyndamax patent, delaying competition
    Pfizer announced it has obtained an extension that pushes back the start of generic competition for its heart-failure drug Vyndamax (tafamidis) by about two years. Vyndamax ranks among Pfizer’s to…
    Endpoints · 6mo agoRegulatoryPositive↗ source
  • FDA commissioner touts real-time trial monitoring to cut drug development dead time
    The Food and Drug Administration announced a new approach that will let regulators view clinical trial endpoints as they happen, using cloud‑based data streams. The move targets the long delays th…
    STAT · 6mo agoRegulatoryPositive↗ source
  • Supreme Court to hear arguments on generic fish‑oil pill case, industry watches
    The U.S. Supreme Court is set to hear arguments this week on a case involving a prescription‑strength pill derived from fish oil. The dispute centers on whether the product qualifies as a generic…
    Endpoints · 6mo agoRegulatoryNeutral↗ source
  • Supreme Court to Hear Arguments on “Skinny Labeling” Case Impacting Generic Drug Access
    The U.S. Supreme Court scheduled oral arguments for Wednesday on a case concerning “skinny labeling,” a practice used by generic drug makers. Skinny labeling involves seeking approval to market a…
    STAT · 6mo agoRegulatoryNeutral↗ source